We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Federal Trade Commission is taking drugmakers to task for tweaking products to maintain exclusivity and block generic competition, warning the practice — known as product hopping — may violate antitrust laws. Read More
The Patent Trial and Appeal Board has invalidated a patent for Novartis’ multiple sclerosis drug Gilenya, in one of the first successful uses of the inter partes review process by generics drugmakers. Read More
U.S. companies taking new biologicals to 11 Pacific Rim nations would get no more than eight years of marketing exclusivity — four less than what they enjoy in the U.S. — under a trade deal agreed to by all 12 countries. Read More
A British charity is pledging roughly $154 million over the next five years toward research into treatments and diagnostics to improve cancer survival. Read More
The FDA is warning healthcare providers and patients not to use sterile drugs made by an Oklahoma compounder after the firm refused to cease sterile operations following a failed inspection — the latest in a stream of safety alerts, warning letters and Form 483s having to do with compounders’ sterility practices over the past year. Read More
Eli Lilly is suspending development of its leading heart drug candidate evacetrapib after an independent data monitoring committee determined it wasn’t effective in a Phase 3 clinical trial. Read More
Presidential candidate and Senate HELP Committee member Bernie Sanders said Friday that he plans to vote against confirming Robert Califf as the new FDA commissioner, citing Califf’s strong ties to industry. Read More